Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 215 publications
Current Management of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in a Changing Landscape.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 13, 2026
Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 15, 2026
Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.
Journal: Circulation
Published: June 15, 2026
Erratum: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 04, 2026
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 09, 2026
Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 13, 2025
Cardiotoxic Effects of Antibody Drug Conjugates vs Standard Chemotherapy in ERBB2-Positive Advanced Breast Cancer: A Systematic Review and Meta-Analysis.
Journal: JAMA network open
Published: November 09, 2025
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.
Journal: The New England journal of medicine
Published: October 22, 2025
Beamion BCGC-1: phase Ib/II trial of zongertinib for advanced HER2-positive breast or gastroesophageal cancers.
Journal: Future oncology (London, England)
Published: October 18, 2025
Corrigendum to "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3": [Ann Oncol 2024; 35: 718-727].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 15, 2025
Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.
Journal: JAMA oncology
Published: September 25, 2025
Last Updated: 09/26/2026